U.S. regulators have approved a new drug that harnesses the immune system to treat advanced bladder cancer.
The Food and Drug Administration on Monday approved Imfinzi (im-fin-ZEE') along with a companion diagnostic test for identifying which patients are most likely to benefit from it.
Imfinzi, also known as durvalumab, is part of a new generation of immuno-oncology drugs, which stimulate the immune system to help fight cancer.
AstraZeneca, Imfinzi's developer, says the average monthly list price for Imfinzi is roughly $15,000, but varies with the patient's weight. It's infused every two weeks.
Bladder cancer is the sixth most common type of cancer in the U.S., and is usually fatal when it recurs.
AstraZeneca is testing the drug against numerous cancers.